Document is current
Any future updates will be listed below
-
Authors
Carbonell-Asins, Juan Antonio
Jiménez-Martí, Elena
Romero, Sergio
García, Eduardo
Miralles-Marco, Ana
Lopez, Beatriz
Huerta, Marisol
Caballero, Carmelo
Boggino, Hugo
Gauna, Cinthia
Acevedo-Funes, Olga Beatriz
Nuñez, Gabriel Benitez
Céspedes-Cardozo, Claudia Melina
Fernandez-Figueroa, Edith A.
Ortiz-Olvera, Nayeli
Ruiz-García, Erika
Carneiro, Fátima
Barros, Rita
Figueiredo, Ceu
Ferreira, Rui M.
Groen - van Schooten, Tessa Suzanne
van Santvliet, Demi
Derks, Sarah
Luca, Romina
Alsina, Maria
Riquelme, Arnoldo
Cervantes, Andrés
Fleitas, Tania https://orcid.org/0000-0002-2789-9082
-
Funding
Funding for this research was provided by:
Horizon 2020 Framework Programme (GA825832)
CONAHCYT (297681)
- License Information
-
More Information
Article History
Accepted: 1 February 2025
First Online: 13 February 2025
Declarations
:
: The HCUV Ethical Committee (IRB) from Hospital Clínico Universitario de Valencia, Valencia, Spain, approved the online questionnaires (Reference 2018.205 and 2018.205 MSnº5). The study was conducted following the standards of Good Clinical Practice. All participants provided written informed consent before enrolment through the online form. Data was anonymized prior to the analysis by eliminating all possible sensitive data. The study will be conducted according to the principles of the declaration of Helsinki (Fortaleza, Brazil, October 2013) and in accordance with the Medical Research Involving Human Subjects Act.
: Cinthia V Gauna reports a relationship with Bristol Myers Squibb Co. that includes speaking and lecture fees; Abbott Laboratories that includes speaking and lecture fees; Farmaceutica Paraguaya that includes speaking and lecture fees and travel reimbursement; Roche that includes travel reimbursement; and Laboratorios Tuteur SA that includes travel reimbursement. Erika Ruiz reports a relationship with Roche that includes speaking and lecture fees; Amgen Inc. that includes speaking and lecture fees; Bristol Myers Squibb Co. that includes speaking and lecture fees; Bayer Corporation that includes speaking and lecture fees and travel reimbursement; Merck Research that includes speaking and lecture fees; and Sanofi that includes travel reimbursement; Gilead Sciences Inc. that includes travel reimbursement. Sarah Derks reports a relationship with Incyte Diagnostics that includes funding grants; Bristol Myers Squibb Co. that includes board membership, consulting or advisory, and speaking and lecture fees; Servier Monde that includes speaking and lecture fees and travel reimbursement; and Benecke that includes speaking and lecture fees. Maria Alsina reports a relationship with Merck Sharp & Dohme UK Ltd. that includes consulting or advisory, speaking and lecture fees, and travel reimbursement; BeiGene that includes consulting or advisory; Bristol Myers Squibb Co. that includes consulting or advisory; and AstraZeneca Pharmaceuticals LP that includes consulting or advisory. Andres Cervantes reports a relationship with Actuate Therapeutics Inc. that includes funding grants; Adaptimmune Ltd. that includes funding grants; Affimed GmbH that includes funding grants; Amgen Inc. that includes board membership, funding grants, and speaking and lecture fees; Astellas Pharma Inc. that includes funding grants; AstraZeneca Pharmaceuticals LP that includes funding grants; Bayer Corporation that includes funding grants; F-Star Therapeutics Inc. that includes funding grants; Genentech Inc. that includes funding grants; Gilead Sciences Inc. that includes funding grants; Janssen Pharmaceuticals Inc. that includes funding grants; Eli Lilly and Company that includes funding grants; MedImmune LLC that includes funding grants; Merck Serono that includes board membership, funding grants, and speaking and lecture fees; Merck Sharp & Dohme UK Ltd. that includes funding grants; Natera Inc. that includes funding grants; Novartis that includes funding grants; Ribon Therapeutics Inc. that includes funding grants; Roche that includes board membership, funding grants, and speaking and lecture fees; Takeda Oncology that includes funding grants; Foundation Medicine Inc. that includes speaking and lecture fees; AbbVie Inc. that includes board membership; AnHeart Therapeutics that includes board membership; GSK that includes board membership; Transgene SA that includes board membership; and Clinical Investigation Foundation of Valencia that includes non-financial support. Tania Fleitas reports a relationship with Merck Sharp & Dohme UK Ltd. that includes consulting or advisory and speaking and lecture fees; AstraZeneca Pharmaceuticals LP that includes consulting or advisory; Amgen Inc. that includes consulting or advisory and speaking and lecture fees; Gilead Sciences Inc. that includes funding grants; Bristol Myers Squibb Co. that includes speaking and lecture fees; Roche that includes speaking and lecture fees and travel reimbursement; Eli Lilly and Company that includes speaking and lecture fees and travel reimbursement; and Servier Monde that includes speaking and lecture fees. Andres Cervantes is the ESMO President and associated editor of ESMO Open and Annals of Oncology. He is also the editor-in-chief of Cancer Treatment Reviews. Tania Fleitas is an evaluator of European Grants for the European Commission. Marisol Huerta declares advisory board and speaker fees from Servier. With respect the other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
: The clinical trial described in this paper was registered at Clinicaltrials.gov under the registration number NCT04019808 (Legacy 3) on July 15th, 2019.
